Diabetes Health Fair Set for Saturday at Winter Haven Hospital
Obese children face an increased risk of adult obesity and all the health risks that come with it, including Type 2 diabetes. By connecting children with healthy, affordable food options and the opportunity to be active in their communities, Let’s Move! is helping our sons and daughters reach a healthier, more promising tomorrow. This month, as we remember those we have lost to diabetes and support those living with the illness, let us look to a day with fewer cases of diabetes, a firmer understanding of the disease, and better outcomes for all those affected. By continuing the important research, outreach, and care delivery we have already begun, we know we can get there.
For the original version including any supplementary images or video, visit http://www.whitehouse.gov/the-press-office/2013/10/31/presidential-proclamation-national-diabetes-month-2013
WINTER HAVEN | Winter Haven Hospital has a huge potential audience for the Diabetes Health Fair being held there on Saturday. About 1 in 10 adults in Florida, 10.4 percent, have been diagnosed with diabetes and others are at risk of getting it. Polk County’s 14.2 percentage is higher than Florida’s. “There are so many people in the United States, in Florida and Polk County who have diabetes who don’t know they have it, or know they have it but don’t realize the impact on their health,” said registered nurse Joanne Vaccaro-Kish, a certified diabetes educator who coordinates the hospital’s Center for Diabetes Education. The fair, from 8 a.m.
For the original version including any supplementary images or video, visit http://www.theledger.com/article/20131107/NEWSCHIEF/131109342/1007/news37
Salix to Buy Santarus for $2.6 Billion for Diabetes Drug
Salix, based in Raleigh, North Carolina , will pay $32 a share in cash for San Diego-based Santarus, a 39 percent premium to Santaruss average closing price in the last 30 trading days, the companies said in a statement. The combined company will have revenue of $1.3 billion and benefit from merging two sales forces and increasing its slate of experimental drugs, Salix Chief Executive Officer Carolyn Logan said in the statement. Salixs top-selling drug is Xifaxan, for travelers diarrhea, which drew $514.5 million in 2012 sales . Santarus sells Glumetza for Type 2 diabetes , which analysts estimate will generate $221.6 million in 2015 revenue, and Zegerid for heartburn, forecast for $106.3 million in sales.
For the original version including any supplementary images or video, visit http://www.bloomberg.com/news/2013-11-07/salix-to-buy-santarus-for-2-6-billion-for-diabetes-drug.html